Brothers Sudhir and Samir Mehta have resurrected the company after Torrent Pharma lost 70 percent of its business when the erstwhile Soviet Union collapsed in 1991. A good track record of securing approval for new drugs in the US has helped the company. But as pricing pressure in the US impacts Indian pharma companies, a couple of strategic acquisitions made in India are likely to help offset any weakness.